202 related articles for article (PubMed ID: 34001908)
1. Polymer-free corticosteroid dimer implants for controlled and sustained drug delivery.
Battiston K; Parrag I; Statham M; Louka D; Fischer H; Mackey G; Daley A; Gu F; Baldwin E; Yang B; Muirhead B; Hicks EA; Sheardown H; Kalachev L; Crean C; Edelman J; Santerre JP; Naimark W
Nat Commun; 2021 May; 12(1):2875. PubMed ID: 34001908
[TBL] [Abstract][Full Text] [Related]
2. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis.
Luo L; Yang J; Oh Y; Hartsock MJ; Xia S; Kim YC; Ding Z; Meng T; Eberhart CG; Ensign LM; Thorne JE; Stark WJ; Duh EJ; Xu Q; Hanes J
J Control Release; 2019 Feb; 296():68-80. PubMed ID: 30660629
[TBL] [Abstract][Full Text] [Related]
3. Injectable liquid polymers extend the delivery of corticosteroids for the treatment of osteoarthritis.
Rivera-Delgado E; Djuhadi A; Danda C; Kenyon J; Maia J; Caplan AI; von Recum HA
J Control Release; 2018 Aug; 284():112-121. PubMed ID: 29906555
[TBL] [Abstract][Full Text] [Related]
4. Influence of the test method on in vitro drug release from intravitreal model implants containing dexamethasone or fluorescein sodium in poly (d,l-lactide-co-glycolide) or polycaprolactone.
Stein S; Auel T; Kempin W; Bogdahn M; Weitschies W; Seidlitz A
Eur J Pharm Biopharm; 2018 Jun; 127():270-278. PubMed ID: 29490233
[TBL] [Abstract][Full Text] [Related]
5. A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema.
Daull P; Paterson CA; Kuppermann BD; Garrigue JS
J Ocul Pharmacol Ther; 2013 Mar; 29(2):258-69. PubMed ID: 23331052
[TBL] [Abstract][Full Text] [Related]
6. Formulation and ex vivo evaluation of polymeric nanoparticles for controlled delivery of corticosteroids to the skin and the corneal epithelium.
Balzus B; Sahle FF; Hönzke S; Gerecke C; Schumacher F; Hedtrich S; Kleuser B; Bodmeier R
Eur J Pharm Biopharm; 2017 Jun; 115():122-130. PubMed ID: 28189623
[TBL] [Abstract][Full Text] [Related]
7. Controlled release of low-molecular weight, polymer-free corticosteroid coatings suppresses fibrotic encapsulation of implanted medical devices.
Pakshir P; Younesi F; Wootton KA; Battiston K; Whitton G; Ilagan B; Louka D; Statham M; Mackey G; Daley A; Parrag I; Naimark W; Hinz B
Biomaterials; 2022 Jul; 286():121586. PubMed ID: 35635896
[TBL] [Abstract][Full Text] [Related]
8. Anti-Inflammatory Effect of Dexamethasone Controlled Released From Anterior Suprachoroidal Polyurethane Implants on Endotoxin-Induced Uveitis in Rats.
Barbosa Saliba J; Vieira L; Fernandes-Cunha GM; Rodrigues Da Silva G; Ligório Fialho S; Silva-Cunha A; Bousquet E; Naud MC; Ayres E; Oréfice RL; Tekaya M; Kowalczuk L; Zhao M; Behar-Cohen F
Invest Ophthalmol Vis Sci; 2016 Apr; 57(4):1671-9. PubMed ID: 27054520
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone Degradation in Aqueous Medium and Implications for Correction of In Vitro Release from Sustained Release Delivery Systems.
Matter B; Ghaffari A; Bourne D; Wang Y; Choi S; Kompella UB
AAPS PharmSciTech; 2019 Oct; 20(8):320. PubMed ID: 31646399
[TBL] [Abstract][Full Text] [Related]
10. Supramolecular aggregates of cyclodextrins with co-solvent modulate drug dispersion and release behavior of poorly soluble corticosteroid from chitosan membranes.
do Nascimento EG; de Azevedo EP; Alves-Silva MF; Aragão CFS; Fernandes-Pedrosa MF; da Silva-Junior AA
Carbohydr Polym; 2020 Nov; 248():116724. PubMed ID: 32919548
[TBL] [Abstract][Full Text] [Related]
11. Preparation of dexamethasone ophthalmic implants: a comparative study of in vitro release profiles.
Prata AI; Coimbra P; Pina ME
Pharm Dev Technol; 2018 Mar; 23(3):218-224. PubMed ID: 28300463
[TBL] [Abstract][Full Text] [Related]
12. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.
Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB
J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403
[No Abstract] [Full Text] [Related]
13. Cytotoxicity considerations and electrically tunable release of dexamethasone from polypyrrole for the treatment of back-of-the-eye conditions.
Ramtin A; Seyfoddin A; Coutinho FP; Waterhouse GI; Rupenthal ID; Svirskis D
Drug Deliv Transl Res; 2016 Dec; 6(6):793-799. PubMed ID: 26887593
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic Acid-Based Micelles as Ocular Platform to Modulate the Loading, Release, and Corneal Permeation of Corticosteroids.
Bongiovì F; Di Prima G; Palumbo FS; Licciardi M; Pitarresi G; Giammona G
Macromol Biosci; 2017 Dec; 17(12):. PubMed ID: 29144603
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide.
Wang C; Hou H; Nan K; Sailor MJ; Freeman WR; Cheng L
Exp Eye Res; 2014 Dec; 129():74-82. PubMed ID: 25446320
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Sustained Release from a Biodegradable Photo-Cross-Linked Network for Intraocular Corticosteroid Delivery.
Amsden BG; Marecak D
Mol Pharm; 2016 Sep; 13(9):3004-12. PubMed ID: 27323900
[TBL] [Abstract][Full Text] [Related]
17. Electro-responsive macroporous polypyrrole scaffolds for triggered dexamethasone delivery.
Seyfoddin A; Chan A; Chen WT; Rupenthal ID; Waterhouse GI; Svirskis D
Eur J Pharm Biopharm; 2015 Aug; 94():419-26. PubMed ID: 26141345
[TBL] [Abstract][Full Text] [Related]
18. A potential nanoparticle-loaded in situ gel for enhanced and sustained ophthalmic delivery of dexamethasone.
Wen Y; Ban J; Mo Z; Zhang Y; An P; Liu L; Xie Q; Du Y; Xie B; Zhan X; Tan L; Chen Y; Lu Z
Nanotechnology; 2018 Oct; 29(42):425101. PubMed ID: 30074486
[TBL] [Abstract][Full Text] [Related]
19. Controlled Release of Dexamethasone From an Intravitreal Delivery System Using Porous Silicon Dioxide.
Hou H; Wang C; Nan K; Freeman WR; Sailor MJ; Cheng L
Invest Ophthalmol Vis Sci; 2016 Feb; 57(2):557-66. PubMed ID: 26882530
[TBL] [Abstract][Full Text] [Related]
20. Plasma concentration of metformin and dexamethasone after administration through Osseogate.
Kim HK; Park YS
Drug Deliv; 2017 Nov; 24(1):437-442. PubMed ID: 28165808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
